Neon Therapeutics
Focused on unlocking the full potential of the immune system to recognize and attack cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
$67.0m Valuation: $67.0m 6.7x EV/Revenue -1.1x EV/EBITDA | Acquisition | ||
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (600 %) |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | - | - | (670 %) |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Neon Therapeutics, a company acquired by BioNTech in 2020, operated in the immuno-oncology sector with a focus on developing neoantigen-targeted therapies for cancer treatment. The company was founded in 2013 by a distinguished group of individuals including Nir Hacohen, Stephen Hoge, Eric Lander, Robert Langer, James Allison, Ton Schumacher, and Pardis Sabeti, emerging from stealth mode in 2015. This team brought together extensive expertise in genomics, immunology, and drug delivery, which was foundational to the company's scientific approach.
The core of Neon Therapeutics' strategy was the development of personalized cancer treatments. Their lead candidate, NEO-PV-01, was a personal cancer vaccine custom-designed for each patient based on the unique neoantigens—mutations found exclusively on cancer cells. This vaccine was intended to be used in combination with checkpoint inhibitors to stimulate a tailored immune response against a patient's specific tumor. The company also developed a T-cell therapy program, NEO-PTC-01, which involved extracting, selecting, and expanding a patient's own T-cells that were naturally reactive to their cancer's neoantigens. Beyond personalized therapies, Neon Therapeutics was also advancing a shared neoantigen program, targeting common mutations found across certain cancer patient populations.
Financially, Neon Therapeutics achieved several significant milestones. The company raised a total of $241 million through various funding rounds, including a $106 million Series B financing in 2017. It went on to successfully launch an Initial Public Offering (IPO) in June 2018, raising $100 million. Ultimately, the company's journey culminated in its acquisition by BioNTech in May 2020 for $67 million, a move that integrated Neon's neoantigen expertise and its US-based team into BioNTech's global operations.
Keywords: immuno-oncology, neoantigen therapies, cancer treatment, personalized medicine, T-cell therapy, cancer vaccines, clinical-stage, genomics, BioNTech acquisition, biopharmaceutical